Lit Matters #2: Macrolides Make a Return for Inpatient CAP

Hospitalized pneumococcal pneumonia is not just an “atypical coverage” question. In bacteremic community-acquired pneumonia, adding a macrolide to beta-lactam therapy was associated with lower in-hospital mortality, while respiratory fluoroquinolones did not show the same signal.

Macrolides in Inpatient Pneumococcal CAP

• Guideline context shift: The 2020 IDSA CAP guidelines moved away from routine macrolide use for outpatients because of Streptococcus pneumoniae resistance, but hospitalized patients remained a different clinical lane.
• Bacteremic CAP mortality signal: In culture-confirmed bacteremic pneumococcal pneumonia, macrolide exposure was associated with better survival from 72 hours after admission to discharge, a clinically meaningful finding in a cohort with about 20% mortality.
• Azithromycin over quinolones: Azithromycin showed the clearest survival association, whereas respiratory fluoroquinolones did not demonstrate a significant mortality benefit in this hospitalized strep pneumo population.
• More than atypical coverage: The proposed mechanism is immunomodulation: macrolides may blunt pneumolysin-driven inflammation, which helps explain benefit even when the pathogen is already known to be Streptococcus pneumoniae. We get into that pathophysiology in the episode.
• Short-course benefit signal: Even fewer than 2 days of macrolide therapy still tracked with improved survival, suggesting the advantage may come early rather than requiring a prolonged add-on course.
• Practice-changing caution: This was a retrospective nationwide cohort, not an RCT, so the signal is hypothesis-strengthening rather than definitive; the inpatient severity context is the key nuance we walk through in the chapter.